Vaccine Administration Articles & Analysis
17 news found
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. ...
About PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
Important Safety Information (ISI) Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of ...
Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. ...
About PreHevbrio™ VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
About VBI’s 3-Antigen HBV Vaccine VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
(Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. ...
ByVaxxinit
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. ...
The findings build on Vaxxas’ existing pre-clinical and clinical data assessing its HD-MAP technology for vaccine administration, including a previous study in collaboration with the World Health Organization (WHO) that involved a simulation of vaccine administration using the HD-MAP with children in Low and Middle-Income ...
About PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] / PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
"Due to the potential for anti-vector immunity after primary Ervebo vaccination, boosting with the same vaccine several years later may not be possible. INOVIO's DNA vaccine candidate INO-4201 has the potential to serve as a booster in the setting of prior Ervebo vaccination depending on its tolerability after multiple ...
ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats. ...
The UAE leads the way in terms of the percentage of its population which could be covered by the number of vaccines that it has administered. According to the stats provided by Bloomberg’s COVID-19 tracker, the UAE has given 15.6 million doses of a viable vaccine to its citizens, which is sufficient to cover 72.4% of the population. ...
An effective COVID-19 disease model could be of huge benefit as society strives to tackle new strains and mutations of the virus, the complexity of the pathophysiology of the infection, and uncertainties around changing vaccination administration schedules. François-Henri Boissel, CEO, NOVA, said: “Sanofi is a global leader in the pharma sector and ...
IEG President Lorenzo Cagnoni says, ´Fundamental strategic choices made to keep the engines running, now ready to take off again along with the companies with an overall replanning of the calendar and formats of the events foreseen in the first part of 2021.´ The gradual administration of vaccine throughout the world and simultaneous discussion by the ...
(Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies including a Phase 1 trial of an FDA-approved seasonal ...
This new research contract comes after Micron successfully completed a Phase 1 SBIR grant and a research contract with the CDC for the development of a microneedle patch for the administration of inactivated rotavirus vaccine (IRV) and co-administration of IRV and inactivated poliovirus vaccine (IPV). ...